Sees FY25 total revenue guidance of $1.03B to $1.095B, including DAYBUE net sales guidance of $380M to $405M and NUPLAZID net sales guidance of $650M to $690M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD: